222 related articles for article (PubMed ID: 29113548)
1. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Prokofyeva A; Loparev S
Aging Male; 2018 Jun; 21(2):121-129. PubMed ID: 29113548
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
3. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
[TBL] [Abstract][Full Text] [Related]
5. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
[TBL] [Abstract][Full Text] [Related]
6. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Am J Mens Health; 2016 Mar; 10(2):157-63. PubMed ID: 26186951
[TBL] [Abstract][Full Text] [Related]
8. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
Shin YS; Zhang LT; You JH; Choi IS; Zhao C; Park JK
Clin Interv Aging; 2016; 11():1301-1307. PubMed ID: 27698559
[TBL] [Abstract][Full Text] [Related]
10. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
Sakalis V; Sfiggas V; Vouros I; Salpiggidis G; Papathanasiou A; Apostolidis A
Int J Urol; 2018 Aug; 25(8):737-745. PubMed ID: 30008188
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
[TBL] [Abstract][Full Text] [Related]
12. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Dimitropoulos K; Gravas S
Drug Des Devel Ther; 2015; 9():1707-16. PubMed ID: 25834406
[TBL] [Abstract][Full Text] [Related]
13. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
Lee SH; Byun SS; Lee SJ; Kim KH; Lee JY
Int Urol Nephrol; 2014 Mar; 46(3):523-9. PubMed ID: 24097273
[TBL] [Abstract][Full Text] [Related]
14. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
[TBL] [Abstract][Full Text] [Related]
16. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
Yamanishi T; Asakura H; Seki N; Tokunaga S
Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585
[TBL] [Abstract][Full Text] [Related]
18. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
[TBL] [Abstract][Full Text] [Related]
19. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis.
Gong M; Dong W; Huang G; Gong Z; Deng D; Qiu S; Yuan R
Curr Med Res Opin; 2015; 31(9):1781-92. PubMed ID: 26211817
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Kaplan SA; Herschorn S; McVary KT; Staskin D; Chapple C; Foley S; Cambronero Santos J; Kristy RM; Choudhury N; Hairston J; Schermer CR
J Urol; 2020 Jun; 203(6):1163-1171. PubMed ID: 31895002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
